Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Offering SARS-CoV-2 test
Eligibility
Inclusion Criteria:
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county
with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and
Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion Criteria:
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum
samples drawn during routine dialysis care (i.e., without an additional
needlestick). If a patient declines offered testing he/she will still be part of
the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of
participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shuchi Anand, MD
6507252207
Not Recruiting
Psoriasis Clinical Trials
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Offering SARS-CoV-2 test
Eligibility
Inclusion Criteria:
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county
with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and
Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion Criteria:
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum
samples drawn during routine dialysis care (i.e., without an additional
needlestick). If a patient declines offered testing he/she will still be part of
the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of
participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shuchi Anand, MD
6507252207
Not Recruiting
Dermatology Clinical Trials
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Offering SARS-CoV-2 test
Eligibility
Inclusion Criteria:
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county
with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and
Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion Criteria:
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum
samples drawn during routine dialysis care (i.e., without an additional
needlestick). If a patient declines offered testing he/she will still be part of
the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of
participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shuchi Anand, MD
6507252207
Not Recruiting
Pediatric Dermatology Clinical Trials
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Offering SARS-CoV-2 test
Eligibility
Inclusion Criteria:
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county
with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and
Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion Criteria:
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum
samples drawn during routine dialysis care (i.e., without an additional
needlestick). If a patient declines offered testing he/she will still be part of
the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of
participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shuchi Anand, MD
6507252207
Not Recruiting
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Offering SARS-CoV-2 test
Eligibility
Inclusion Criteria:
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county
with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and
Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion Criteria:
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum
samples drawn during routine dialysis care (i.e., without an additional
needlestick). If a patient declines offered testing he/she will still be part of
the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of
participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shuchi Anand, MD
6507252207
Not Recruiting
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are more likely to be older, non-white, from disadvantaged backgrounds, and have impaired immune responses to viral infections and vaccinations. Universal testing offered at hemodialysis facilities could shield this vulnerable population from exposure, enable early identification and treatment for those affected, and reduce transmission to other patients and family members. In this pragmatic cluster randomized controlled trial as part of NIH RADx-UP Consortium, we will randomize 62 US Renal Care facilities with an estimated 2480 patients to static versus dynamic universal screening testing strategies. Static universal screening will involve offering patients SARS-CoV-2 screening tests every two weeks; the dynamic universal screening strategy will vary the frequency of testing from once every week to once every four weeks, depending on community COVID-19 case rates. We hypothesize that patients dialyzing at facilities randomized to a dynamic testing frequency responsive to community case rates will have higher test acceptability (primary outcome), experience lower rates of COVID-19 death and hospitalization, and report better experience-of-care metrics.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- behavioral: Offering SARS-CoV-2 test
Eligibility
Inclusion Criteria:
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county
with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and
Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion Criteria:
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum
samples drawn during routine dialysis care (i.e., without an additional
needlestick). If a patient declines offered testing he/she will still be part of
the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of
participation
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shuchi Anand, MD
6507252207
Not Recruiting